Dementia treatment biotech Kinoxis Therapeutics has raised $6.75 million in equity funding alongside nailing a $2.5 million government grant from the federal government’s Medical Research Future Fund.
Deep tech VC Main Sequence led the round, chipping in $5m as a new investor, with principal Elaine Stead appointed a director. The grant comes via the CUREator+ Dementia & Cognitive Decline program, delivered by Brandon BioCatalyst, ANDHealth and Dementia Australia.
The cash will go towards developing drugs for agitation associated with dementia.
The Sydney University spinout, founded in 2017, and now based in Melbourne, previously raised a $14.5m Series B two years ago and a $5m Series A2 in December 2020.
The cap table also include Uniseed, UniSuper, Sydney Uni, Stoic VC, and US-based Avicella Capital, as well as several sophisticated investors.
The $9.25 million in new cash is for clinical trials and treatments for dementia-related agitation and pain.
Get the best of Startup Daily straight to your inbox
By continuing, you agree to our Terms & Conditions and Privacy Policy.
Its most advanced drug candidate, KNX100, is being tested in a Phase 2 clinical trial called CARES-X. The study is assessing the short-acting drug for both persistent agitation and the rapid treatment of acute episodes in people with dementia.
The trial has passed half its recruitment target, with initial results expected in mid-2027.
Recruitment has expanded to include hospital dementia wards and residential aged care facilities, allowing people with more advanced dementia and more severe or frequent agitation to participate.
The CUREator+ grant will fund work on KNX101, a longer-acting drug candidate for dementia-related chronic agitation and aggression.
Kinoxis expects to begin toxicology studies, which assess potential harmful effects ahead of human trials, by the end of 2026.
Kinoxis is also developing longer-acting drug candidates for acute and chronic pain and also plans to pursue partnerships to support development and commercialisation of treatments for brain-related conditions and pain.
Dementia treatment biotech Kinoxis Therapeutics has raised $6.75 million in equity funding alongside nailing a $2.5 million government grant from the federal government’s Medical Research Future Fund.
Deep tech VC Main Sequence led the round, chipping in $5m as a new investor, with principal Elaine Stead appointed a director. The grant comes via the CUREator+ Dementia & Cognitive Decline program, delivered by Brandon BioCatalyst, ANDHealth and Dementia Australia.
The cash will go towards developing drugs for agitation associated with dementia.
The Sydney University spinout, founded in 2017, and now based in Melbourne, previously raised a $14.5m Series B two years ago and a $5m Series A2 in December 2020.
The cap table also include Uniseed, UniSuper, Sydney Uni, Stoic VC, and US-based Avicella Capital, as well as several sophisticated investors.
The $9.25 million in new cash is for clinical trials and treatments for dementia-related agitation and pain.
Get the best of Startup Daily straight to your inbox
By continuing, you agree to our Terms & Conditions and Privacy Policy.
Its most advanced drug candidate, KNX100, is being tested in a Phase 2 clinical trial called CARES-X. The study is assessing the short-acting drug for both persistent agitation and the rapid treatment of acute episodes in people with dementia.
The trial has passed half its recruitment target, with initial results expected in mid-2027.
Recruitment has expanded to include hospital dementia wards and residential aged care facilities, allowing people with more advanced dementia and more severe or frequent agitation to participate.
The CUREator+ grant will fund work on KNX101, a longer-acting drug candidate for dementia-related chronic agitation and aggression.
Kinoxis expects to begin toxicology studies, which assess potential harmful effects ahead of human trials, by the end of 2026.
Kinoxis is also developing longer-acting drug candidates for acute and chronic pain and also plans to pursue partnerships to support development and commercialisation of treatments for brain-related conditions and pain.
投资人评论
聊判断，不堆黑话登录且账号审核通过后可评论。 立即登录